Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of diabetes
3.2.1.2 Advancements in therapeutic and diagnostic techniques
3.2.1.3 Rising awareness about diabetic complications
3.2.2 Industry pitfalls & challenges
3.2.2.1 High costs of treatment
3.2.2.2 Availability of alternative therapies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends
3.9 Gap analysis
3.10 Pipeline analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Peripheral neuropathy
5.3 Autonomic neuropathy
5.4 Proximal neuropathy
5.5 Focal neuropathy
Chapter 6 Market Estimates and Forecast, By Treatment, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Drug class
6.2.1 Antidepressants
6.2.2 Anticonvulsants
6.2.3 Non-steroidal anti-inflammatory drugs (NSAIDS)
6.2.4 Opioid
6.2.5 Other drug classes
6.3 Radiotherapy and physiotherapy
6.4 Other treatments
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Abbott
9.2 Boehringer Ingelheim GmbH
9.3 Eli Lilly and Company
9.4 Glenmark Pharmaceuticals Ltd
9.5 Janssen Pharmaceuticals, Inc
9.6 Lupin Pharmaceuticals
9.7 MEDA Pharma GmBH & Co. KG
9.8 Pfizer Inc
